These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 17022868)

  • 1. Management of hand-foot syndrome induced by capecitabine.
    Gressett SM; Stanford BL; Hardwicke F
    J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
    Lassere Y; Hoff P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
    Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
    Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
    Kara IO; Sahin B; Erkisi M
    Breast; 2006 Jun; 15(3):414-24. PubMed ID: 16188440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].
    Takeda K; Shigematsu T; Shirai M; Yamagiwa K; Amamori K; Sunda K; Yamanda T
    Gan To Kagaku Ryoho; 2012 Dec; 39 Suppl 1():74-6. PubMed ID: 23268906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
    Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
    J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Management of hand-foot syndrome in patient treated with capecitabine].
    Fujii C; Anami S; Fujino M; Yasui Y; Fujita M; Inoue M; Nakayama T; Kamigaki S; Tatsuta M; Furukawa H
    Gan To Kagaku Ryoho; 2008 Aug; 35(8):1357-60. PubMed ID: 18701848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine and hand-foot syndrome.
    Saif MW
    Expert Opin Drug Saf; 2011 Mar; 10(2):159-69. PubMed ID: 21174613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
    Scheithauer W; Blum J
    Oncology (Williston Park); 2004 Aug; 18(9):1161-8, 1173; discussion 1173-6, 1181-4. PubMed ID: 15471200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical henna ameliorated capecitabine-induced hand-foot syndrome.
    Ilyas S; Wasif K; Saif MW
    Cutan Ocul Toxicol; 2014 Sep; 33(3):253-5. PubMed ID: 24021017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
    Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
    Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress of study on prevention and treatment of xeloda induced hand-foot syndrome by measures of Chinese and Western medicine].
    Wang Y; Xu RR
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Feb; 27(2):182-4. PubMed ID: 17343012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
    Disel U; Gürkut O; Abali H; Kaleağasi H; Mertsoylu H; Ozyilkan O; Saif MW
    Cutan Ocul Toxicol; 2010 Jun; 29(2):140-2. PubMed ID: 20298142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
    Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical henna for capecitabine induced hand-foot syndrome.
    Yucel I; Guzin G
    Invest New Drugs; 2008 Apr; 26(2):189-92. PubMed ID: 17885735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
    Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
    Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
    Jeung HC; Chung HC
    Asia Pac J Clin Oncol; 2010 Sep; 6(3):141-3. PubMed ID: 20887492
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
    Chalermchai T; Tantiphlachiva K; Suwanrusme H; Voravud N; Sriuranpong V
    Asia Pac J Clin Oncol; 2010 Sep; 6(3):155-60. PubMed ID: 20887495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hand and foot syndrome secondary to capecitabine.
    Lal HS
    Indian J Dermatol Venereol Leprol; 2014; 80(5):427-30. PubMed ID: 25201844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.